Pro Health Tips
Saturday, 30 May 2020
Targeted Therapy Pralsetinib Achieves High Response Rates in Advanced Cancers: Study
In patients with RET fusion-positive thyroid cancers, pralsetinib achieved an overall response rate (ORR), said clinical trial results.
from Medindia Health News https://ift.tt/36OGtKT
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
In patients with RET fusion-positive thyroid cancers, pralsetinib achieved an overall response rate (ORR), said clinical trial results.
No comments:
Post a Comment